Reaction Details  Report a problem with these data
Target
Interleukin-2
Ligand
BDBM387272
Substrate
n/a
Meas. Tech.
Inhibition of IL-2 secretion
IC50
<100.0±n/a nM
Citation
 Irlapati, NR; Deshmukh, GK; Karche, VP; Jachak, SM; Sinha, N; Palle, VP; Kamboj, RK Oxazoline and isoxazoline derivatives as CRAC modulators US Patent  US10292981 Publication Date 5/21/2019
Target
Name:
Interleukin-2
Synonyms:
IL-2 | IL2 | IL2_HUMAN | INN=Aldesleukin | Interleukin-2 | Interleukin-2 (IL-2) | T-cell growth factor | TCGF
Type:
Enzyme
Mol. Mass.:
17630.05
Organism:
Homo sapiens (Human)
Description:
P60568
Residue:
153
Sequence:
MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
  
Inhibitor
Name:
BDBM387272
Synonyms:
N-(5-(5- (5,5-dimethyl-4-oxo- 4,5-dihydroisoxazol-3- yl)-2- methylphenyl)pyrazin- 2-yl)-3,5- difluoroisonicotinamide | US10292981, Example 114
Type:
Small organic molecule
Emp. Form.:
C22H17F2N5O3
Mol. Mass.:
437.3989
SMILES:
Cc1ccc(cc1-c1cnc(NC(=O)c2c(F)cncc2F)cn1)C1=NOC(C)(C)C1=O |t:27|
Structure:
Search PDB for entries with ligand similarity: